argenx SE American Depositary Receipt (ARGX)
Are Medical Stocks Lagging Argenx (ARGX) This Year?
Here is how argenex SE (ARGX) and Cardinal Health (CAH) have performed compared to their sector so far this year.
argenx Eyes More VYVGART Growth as Pipeline Catalysts Near
Executives at argenex NASDAQ: ARGX told investors at a Goldman Sachs healthcare event that they continue to see meaningful growth opportunities for VYVGART across myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, while also pointing to a busy slate of pipeline readouts in the second half of the year.
ARGX Shares Gain Nearly 9% in a Month: Here's What You Need to Know
argenx stock rises nearly 9% in a month after the FDA expands Vyvgart's gMG label, opening treatment to adult patients regardless of antibody status.
argenx SE (ARGX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
argenx SE (ARGX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Argenx (ARGX) Soars 5.8%: Is Further Upside Left in the Stock?
Argenx (ARGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
argenx Touts VYVGART Growth, 50,000-Patient Goal at William Blair Conference
argenx NASDAQ: ARGX Chief Financial Officer Karl Gubitz told investors at the 46th Annual William Blair Growth Stock Conference that the biotechnology company remains focused on revenue growth, profitability and execution as it expands the VYVGART franchise and advances additional pipeline assets.
argenx SE (ARGX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
argenx SE (ARGX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Alkeon Capital Management LLC Grows Stock Position in argenex SE $ARGX
Alkeon Capital Management LLC grew its holdings in argenex SE (NASDAQ: ARGX) by 133.3% in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 175,000 shares of the company's stock after acquiring an additional 100,000 shares during the quarter. Alkeon Capital
argenx SE (ARGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
argenx SE (ARGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
argenx: Sights Set On $1,000
argenx continues to outperform expectations, driven by Vyvgart's strong commercial momentum and impressive growth in CIDP and gMG markets. Vyvgart is on track to deliver more than $4.1 billion in net sales in 2025, and there are five late-stage readouts in 2025 that could further improve the long-term outlook. Profitability and robust cash generation add business development as another avenue for growth.
Baron International Growth Fund Q3 2025 Contributors And Detractors
Baron International Growth Fund gained 6.04% during the quarter, slightly underperforming its benchmark, the MSCI ACWI ex USA Index. Lynas Rare Earths' shares nearly doubled during the quarter as geopolitical and trade tensions underscored the strategic importance of supply sources outside China. Constellation Software, a holding company that owns and operates a large portfolio of vertical-market software businesses, detracted from performance.
argenx SE (ARGX) Q3 2025 Earnings Call Transcript
argenx SE ( ARGX ) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDT Company Participants Beth DelGiacco - VP and Global Head of Corporate Communications & Investor Relations Tim Van Hauwermeiren - Co-Founder, CEO & Executive Director Karl Gubitz - Chief Financial Officer Karen Massey - Chief Operating Officer Luc Truyen - Chief Medical Officer Conference Call Participants Rajan Sharma - Goldman Sachs Group, Inc., Research Division Tazeen Ahmad - BofA Securities, Research Division Derek Archila - Wells Fargo Securities, LLC, Research Division Alexander Thompson - Stifel, Nicolaus & Company, Incorporated, Research Division Yatin Suneja - Guggenheim Securities, LLC, Research Division Yaron Werber - TD Cowen, Research Division Danielle Brill Bongero - Truist Securities, Inc., Research Division Amy Li - Jefferies LLC, Research Division Richard Vosser - JPMorgan Chase & Co, Research Division Samantha Semenkow - Citigroup Inc., Research Division Myles Minter - William Blair & Company L.L.C., Research Division Jacob Mekhael - KBC Securities NV, Research Division Thomas Smith - Leerink Partners LLC, Research Division Douglas Tsao - H.C.
